• Citer

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): A randomised, open-label, multicentre, phase 3 trial

par Perez, Edith A;Yardley, Denise;Potter, David D.A.;Mailliez, Audrey;Moreno-Aspitia, Alvaro;Ahn, Jin Seok;Zhao, Carol;Hoch, Ute;Tagliaferri, Mary;Hannah, Alison L;Cortes, Javier;Awada, Ahmad ;O'Shaughnessy, Joyce;Rugo, Hope;Twelves, Chris;Im, Seock Ah;Gómez-Pardo, Patricia;Schwartzberg, Lee L.S.;Diéras, Véronique
Référence Lancet oncology, 16, 15, page (1556-1568)
Publication Publié, 2015

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): A randomised, open-label, multicentre, phase 3 trial
Auteur:	Perez, Edith A; Yardley, Denise; Potter, David D.A.; Mailliez, Audrey; Moreno-Aspitia, Alvaro; Ahn, Jin Seok; Zhao, Carol; Hoch, Ute; Tagliaferri, Mary; Hannah, Alison L; Cortes, Javier; Awada, Ahmad; O'Shaughnessy, Joyce; Rugo, Hope; Twelves, Chris; Im, Seock Ah; Gómez-Pardo, Patricia; Schwartzberg, Lee L.S.; Diéras, Véronique
Informations sur la publication:	Lancet oncology, 16, 15, page (1556-1568)
Statut de publication:	Publié, 2015
Sujet CREF:	Cancérologie
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1470-2045
	info:doi/10.1016/S1470-2045(15)00332-0
	info:pii/S1470204515003320
	info:scp/84960964225
	info:pmid/26482278